ArticleBreast cancer (Dove Medical Press)2026
The Novel ROCK Inhibitor Fasudil Derivative Fasudil-D-6h Prevents Tumour Progression by Regulating the Adherens Junction Signalling Pathway in Triple-Negative Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited therapeutic options. Rho-associated coiled-coil containing protein kinase (ROCK) signaling is a promising target, known to drive tumor progression through cytoskeletal remodelling and epithelial-mesenchymal transition (EMT). However, its role in disrupting epithelial integrity via adherens and tight junctions in TNBC remains underexplored. Fasudil-D-6h is a novel derivative of the clinically approved ROCK inhibitor fasudil. This study investigates the anti-tumor efficacy of fasudil-D-6h and its novel mechanism of action in TNBC. Methods: The effects of fasudil-D-6h and the reference inhibitor HA-1100 on cell proliferation (CCK-8) and apoptosis (flow cytometry) were assessed in MDA-MB-231 and MCF-7 cells. Transcriptome sequencing of fasudil-D-6h-treated MDA-MB-231 cells identified differentially expressed genes (DEGs) and enriched pathways. A protein-protein interaction (PPI) network was constructed. The in vivo efficacy was evaluated in a nude mouse model of subcutaneous MDA-MB-231 tumors. qRT-PCR and Western blotting validated the expression of ROCK1/2 and key adherens junction pathway components (Cdc42, Rac3, Src, ZO-1, Occludin, Claudin-1). Results: Fasudil-D-6h significantly inhibited proliferation and induced apoptosis in TNBC cells. Transcriptomic analysis revealed 8,092 DEGs, with significant enrichment in the adherens junction pathway. Accordingly, fasudil-D-6h treatment in vitro and in vivo significantly downregulated ROCK1/2 and robustly upregulated the expression of CDC42, RAC3, SRC, ZO-1, OCCLUDIN, and CLAUDIN-1. In the mouse model, fasudil-D-6h treatment led to a significant reduction in tumor mass and volume. Discussion: Our findings demonstrate that the novel ROCK inhibitor fasudil-D-6h exerts potent anti-tumor effects in TNBC. Its mechanism of action is distinctively linked to the restoration of genes critical to adherens and tight junction integrity. Given its derivation from the clinically viable fasudil, fasudil-D-6h presents a strong translational potential as a novel therapeutic agent for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.